Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC
A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or metastatic head and neck squamous cell carcinoma
Head and Neck Squamous Cell Carcinoma
DRUG: Docetaxel-PM
Response rate as assessed by RECIST v1.1, Response is confirmed at least 4 weeks later. Assessment: every 6 weeks (treatment period), every 2 months (follow-up period), 2 years
Progression free survival (PFS), Assessment: every 2 months (follow-up period), 2 years|Disease control rate (DCR), DCR is defined as the percentage of patients who have achieved complete response, partial response and stable disease, 2 years|Overall survival, Assessment: every 2 months (follow-up period), 2 years|Number of participants with adverse events as assessed by CTCAE v4.0, 2 years|Incidence rate of hypersensitivity reaction to Docetaxel-PM, 2 years
A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or metastatic head and neck squamous cell carcinoma